Exocrine pancreatic dysfunction is common in hepatocyte nuclear factor 1β–associated renal disease and can be symptomatic by Clissold, Rhian L. et al.
ORIGINAL ARTICLE
Exocrine pancreatic dysfunction is common in
hepatocyte nuclear factor 1b–associated renal disease
and can be symptomatic
Rhian L. Clissold1,2, Jon Fulford1,2, Michelle Hudson1,2, Beverley M. Shields1,
Timothy J. McDonald1, Sian Ellard1, Andrew T. Hattersley1,2 and
Coralie Bingham3
1Institute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, UK, 2National
Institute for Health Research Exeter Clinical Research Facility, Royal Devon and Exeter National Health
Service Foundation Trust, Exeter, UK and 3Exeter Kidney Unit, Royal Devon and Exeter National Health
Service Foundation Trust, Exeter, UK
Correspondence and offprint requests to: Rhian L. Clissold; E-mail: rhian.clissold@nhs.net
Abstract
Background: Heterozygous mutations in the HNF1B gene are the most commonmonogenic cause of developmental kidney
disease. Extrarenal phenotypes frequently occur, including diabetes mellitus and pancreatic hypoplasia; the latter is
associated with subclinical exocrine dysfunction. Wemeasured faecal elastase-1 in patients with HNF1B-associated disease
regardless of diabetes status and assessed the degree of symptoms associated with pancreatic exocrine deficiency.
Methods: Faecal elastase-1 was measured in 29 patients with a known HNF1Bmutation. We defined a low faecal elastase-1
concentration based on the 2.5 percentile of 99 healthy control individuals (410mg/g stool). Symptoms related to pancreatic
exocrine dysfunction were assessed and a subset of the HNF1B cohort (n ¼ 6) underwent pancreatic imaging.
Results: Faecal elastase-1 was below the 2.5 percentile of the control cohort in 18/29 (62%) patients with HNF1B-associated
renal disease. A total of 8/29 (28%) had ameasurement suggestive of exocrine pancreatic insufficiency at <200mg/g stool; of
these, 3 suffered with abdominal pain, loose stools and/or unintentional weight loss. All three experienced symptomatic
improvement and weight gain after commencing pancreatic enzyme replacement therapy. Faecal elastase-1 was low in 7/15
(47%) HNF1B patients without diabetes compared with 11/14 (79%) of those with diabetes (P ¼ 0.1).
Conclusions: Faecal elastase-1 deficiency is a common feature of HNF1B-associated renal disease even when diabetes is not
present and pancreatic exocrine deficiency may be more symptomatic than previously suggested. Faecal elastase-1 should
be measured in all patients with known HNF1B-associated disease complaining of chronic abdominal pain, loose stools or
unintentional weight loss. The discovery of a low faecal elastase-1 concentration in individuals with developmental kidney
disease of uncertain cause should prompt referral for HNF1B genetic testing.
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Introduction
Hepatocyte nuclear factor 1b (HNF1B) is a transcription factor
with important roles in the development of the kidney, pan-
creas, liver and genital tract [1]. Heterozygous mutations of the
HNF1B gene are the most common known monogenic cause of
developmental kidney disease [2–4]. Despite this single genetic
aetiology, the phenotype of HNF1B-associated renal disease is
very variable (Box 1). Biochemical abnormalities, including
hypomagnesaemia and hyperuricaemia, are also frequently
seen [5, 6]. HNF1B-associated disease is a multisystem disorder
and extrarenal phenotypic features include young-onset diabe-
tes mellitus, pancreatic hypoplasia, abnormal liver function
tests and genital tract malformations [7–12]. Genetic changes
comprise either HNF1B intragenic mutations (one-half of
patients) or an approximate 1.3-Mb deletion at chromosome
17q12, which includes the entire HNF1B gene [13, 14]. Both may
arise spontaneously, which means there is often no family his-
tory of renal disease or diabetes [15–17]. In view of the clinical
heterogeneity of the condition and frequent absence of a family
history, diagnosis can be challenging and it is likely that many
cases remain undetected.
Imaging of the pancreas in HNF1B-associated disease with
either computed tomography (CT) or magnetic resonance imag-
ing (MRI) has shown less tissue corresponding to the body and
tail of the pancreas, with a slightly atrophic head [8, 9]. This is
consistent with agenesis of the dorsal pancreas, the embryonic
structure that gives rise to the pancreatic body, tail and a small
section of the head. Pancreatic exocrine hypersecretion has
been observed in patients with HNF1B-associated disease using
secretin-stimulated MRI and rapid endoscopic secretin stimula-
tion tests; this is likely to be a compensatory mechanism for
reduced pancreatic volume and provides further evidence that
the small pancreas seen on imaging is due to hypoplasia rather
than atrophy [18]. A report of 20 foetal autopsy cases with
HNF1B mutations described pancreatic agenesis in 2/20 and
hypoplasia in 13/20 [19].
Pancreatic hypoplasia in HNF1B-associated disease has been
associated with subclinical pancreatic exocrine insufficiency.
This has mainly been studied in small series of patients with
HNF1Bmutations and diabetes using indirect tests of pancreatic
function, usually faecal elastase-1 measurement in stool [8, 9,
20]. Lower exocrine pancreatic function involving both ductal
and acinar cells has been confirmed in direct testing with rapid
endoscopic secretin tests and secretin-stimulated MRI in seven
individuals with HNF1B mutations [18]. To our knowledge, only
one case of symptomatic pancreatic exocrine insufficiency requir-
ing treatment in HNF1B-associated disease has been described in
the literature to date [21]. In this study, our aims were to measure
faecal elastase-1 in patients with HNF1B-associated disease regard-
less of diabetes status and assess the degree of symptoms associ-
ated with pancreatic exocrine deficiency.
Materials and methods
Recruitment and genetic analysis
Participants with HNF1B-associated disease were recruited from 31
January 2013 to 10 October 2015 from three sites in the UK (adult
renal and diabetes units at the Royal Devon and Exeter Hospital;
paediatric renal units at Great Ormond Street Hospital for Children
and Evelina London Children’s Hospital), as previously described
[22]. Inclusion criteria included the presence of either an HNF1B
intragenic mutation or whole-gene deletion on genetic testing per-
formed due to underlying renal abnormalities or diabetes and cur-
rent age 4 years. Informed written consent was obtained from all
adult participants and parents of child participants, with assent
from those <16 years of age. The study was conducted in agree-
ment with the Declaration of Helsinki principles and approved by a
regional ethics committee (National Research Ethics Service
Committee South West—Frenchay). A total of 29 patients from 20
unrelated families with HNF1B-associated disease participated.
Mutation screening was performed by sequencing of coding exons
and exon–intron boundaries together with gene dosage assess-
ment by multiplex ligation–dependent probe amplification as pre-
viously described [14, 17].
Faecal elastase-1 was also measured in a cohort of healthy
controls in order to define a low faecal elastase-1 concentration
based on the 2.5 percentile. Healthy controls were recruited
from 4 March 2015 to 19 August 2016 from two sites in the UK
(National Institute for Health Research Exeter Clinical Research
Facility at the Royal Devon and Exeter Hospital; Oxford Centre
for Diabetes, Endocrinology and Metabolism at the Oxford
University Hospitals National Health Service Foundation Trust).
Inclusion criteria included age 16–75 years, ethnicity reflective
of local demographics and capacity to consent. Informed writ-
ten consent was obtained from all participants. The study was
conducted in agreement with the Declaration of Helsinki princi-
ples and approved by a regional ethics committee (South
West—Frenchay Research Ethics Committee). A total of 99 indi-
viduals participated. The median age of this cohort was 61.7
years [interquartile range (IQR) 52.8–66.3]. A total of 39/99 (39%)
was male and all were of White ethnicity. The median faecal
elastase-1 concentration was 1580 mg/g stool (IQR 1000–2000).
The 2.5 percentile for faecal elastase-1 in this cohort was a con-
centration of 410 mg/g stool (Supplementary data, Figure S1).
There was only a weak association between increasing age and
lower faecal elastase-1 concentrations with a Spearman’s q of
0.2, (P ¼ 0.02) (Supplementary data, Figure S2).
Clinical evaluation
Relevant medical details, including symptoms related to pan-
creatic exocrine dysfunction (abdominal pain, loose stools
and unintentional weight loss), were documented using a
standardized assessment of medical records and participant/
parent interview. Diabetes was diagnosed either according
to World Health Organization guidelines or on the basis of
established treatment with oral hypoglycaemic agents/insulin.
In order to measure endogenous insulin production, the
Box 1. The variable phenotype of HNF1B-associated
renal disease
• Bilateral hyperechogenic kidneys with normal or
slightly increased size on antenatal ultrasonography
• Renal cysts (including cystic dysplasia and multicystic
dysplastic kindney)
• Single kidney
• Renal hypoplasia
• Horseshoe kidney
• Duplex kidney
• Isolated bilateral hydronephrosis and hydroureter
• Collecting system abnormality (usually in conjunction
with other renal structural abnormality)
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urinary C-peptide creatinine ratio (UCPCR) was measured on a
post-prandial urine sample taken approximately 2 h after a
meal stimulus [23].
Faecal elastase-1 concentration was assessed by enzyme-
linked immunosorbent assay on a single spot stool sample at the
Royal Cornwall Hospital; healthy control samples were tested
using a 10 dilution to obtain an absolute value for faecal
elastase-1, as the majority of samples were expected to have a
result greater than the 500 mg/g detection limit of the assay.
Faecal elastase-1 <200 mg/g is considered abnormal, with meas-
urements of 100–200 mg/g suggestive of moderate to mild pancre-
atic exocrine insufficiency and measurements <100 mg/g
suggestive of severe insufficiency [24]. Previous imaging results
from CT or MRI were reviewed to look for pancreas abnormalities.
All patients with HNF1B-associated disease were also invited to
undergo pancreatic MRI using a 1.5-T Philips Intera system utiliz-
ing three-dimensional gradient echo and spin echo sequences,
with and without fat suppression, at a range of orientations.
Images were subsequently reviewed and reported by a consultant
radiologist in order to assess pancreatic structure and ensure
there were no incidental findings of clinical concern.
Statistical analysis
Qualitative variables were described with percentages and
quantitative variables with median and IQR. Differences
between groups were assessed using the Fisher exact test for
categorical variables and the Mann–Whitney U test for conti-
nuous variables. Correlations were tested by Spearman’s q.
A P-value <0.05 was considered to be statistically significant. All
analyses were carried out using StataSE (version 14; StataCorp,
College Station, TX, USA) and GraphPad statistical software
(GraphPad Software, La Jolla, CA, USA).
Results
Participant characteristics
The median age of individuals with HNF1B-associated renal
disease was 25 years (IQR 14–44) and 13/29 (45%) were male. The
majority of the cohort was White, with just 1/29 (3%) being of
mixed ethnicity. A total of 14/29 (48%) had diabetes.
Exocrine pancreatic deficiency is common in HNF1B-
associated disease and can be symptomatic
Faecal elastase-1 was low (below the 2.5 percentile of the con-
trol cohort) in 18/29 (62%) patients with HNF1B-associated renal
disease. In all, 8/29 (28%) had a faecal elastase-1 concentration
suggestive of exocrine pancreatic insufficiency at <200 mg/g
stool (Figure 1); in 4/29 (14%) the measurement was <100 mg/g
stool, in keeping with severe deficiency.
A total of 3/8 individuals with a faecal elastase-1 measure-
ment <200 mg/g stool suffered with abdominal pain, loose stools
and/or unintentional weight loss. All reported symptomatic
improvement and weight gain after commencing pancreatic
enzyme replacement therapy. In all three cases it had taken
several months for symptoms to be attributed to faecal elastase
deficiency and for treatment to be commenced (Table 1).
Individuals with low faecal elastase-1 levels have radio-
logical evidence of pancreatic hypoplasia
In all, 6/29 participants underwent pancreatic imaging with
either CT or MRI. Abnormalities were detected in four of six
participants: one was reported to show diffuse pancreatic atro-
phy with calcification of the head and body plus common bile
duct dilatation, whereas the other three demonstrated absence
or atrophy of the body and tail of the pancreas only. All four
patients had been diagnosed with diabetes and faecal elastase-
1 measurements ranged from 31 to 280 mg/g stool. Two of six
individuals had scans reported within normal limits. One of
these patients was a 20-year-old male without evidence of dia-
betes and a normal faecal elastase-1 result of 432 mg/g stool. The
other patient was a 65-year-old female who had been diagnosed
with new-onset diabetes after transplantation at the age of 62
years and had a faecal elastase-1 result >500 mg/g stool.
Markedly low faecal elastase-1 levels are more common
in HNF1B-associated disease when diabetes is present
Faecal elastase-1 measurements were compared in individuals
with HNF1B-associated disease according to diabetes status. Only
1/15 (7%) of those without diabetes had a markedly low faecal
elastase-1 measurement (<200 mg/g stool) compared to 7/14 (50%)
of those with diabetes (P ¼ 0.01) (Figure 2). Overall, faecal
elastase-1 levels were low in 7/15 (47%) HNF1B patients without
diabetes compared with 11/14 (79%) of those with diabetes (P ¼
0.1). There was only a weak association between increasing dura-
tion of diabetes and lower faecal elastase-1 concentrations, with
a Spearman’s q of0.3 (P ¼ 0.4) (Supplementary data, Figure S3).
The two groups were different with respect to many clinical
characteristics (Table 2). The median age of the cohort without
diabetes was 14 years (IQR 9–19) compared to 43.5 years (IQR 34–
55) in the group with diabetes (P ¼ 0.0005). In those patients
with more severe pancreatic disease, endogenous insulin secre-
tion assessed by the UCP:Cr ratio was lower than in those with-
out diabetes [median UCP:Cr ratio 1.1 nmol/mmol (IQR 0.6–1.5)
compared to 2.1 nmol/mmol (1.4–5.6), respectively; P ¼ 0.04].
Discussion
We have demonstrated that faecal elastase-1 deficiency is com-
mon in HNF1B-associated renal disease and exocrine pancreatic
dysfunction may be more symptomatic than previously pub-
lished. This has important implications for the screening and
treatment of these patients. In all, three of eight individuals in
Fig. 1. Bar chart showing the percentage of individuals with HNF1B-associated
disease with faecal elastase-1 (FE-1) measurements <100 mg/g stool (suggestive
of severe pancreatic exocrine insufficiency), 100–200 mg/g stool (moderate to
mild insufficiency), 200–500 mg/g stool and >500 mg/g stool. The dotted red line
indicates that 3/99 (3%) healthy controls had an FE-1 measurement of 200–500
mg/g stool whereas in the remainder it was >500 mg/g stool.
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this study with a faecal elastase-1 measurement <200 mg/g stool
had abdominal pain, loose stools and weight loss. The only pub-
lished report of symptomatic pancreatic insufficiency in
HNF1B-associated disease involved the identification of diabe-
tes and a small pancreas on imaging in an individual 5 years of
age; pancreatic enzyme replacement therapy became necessary
from the age of 16 years and lead to a normalization of body
mass index [21]. There was a significant delay in attributing
symptoms to pancreatic insufficiency in the three cases identi-
fied in this article, and one of the patients even underwent a
colonoscopy before the correct diagnosis was made. All showed
symptomatic improvement with weight gain once treatment
with pancreatic enzyme replacement therapy was commenced.
This highlights how difficult it can be to diagnose pancreatic
insufficiency and how prompt treatment benefits patients.
Clinicians should have a low threshold for arranging pancreatic
function testing for individuals with known HNF1B-associated
disease, even when subtle symptoms such as mild abdominal
discomfort and bloating are present.
This is the largest series of faecal elastase-1 measurements
in individuals with HNF1B-associated renal disease recruited
irrespective of diabetes status; previous reports of faecal
Table 1. Details of symptomatic faecal elastase deficiency in three individuals with HNF1B-associated renal disease
Patient
Age at
study
entry
(years) Sex Genetic abnormality Diabetes status
FE-1,
mg/g
stool
Pancreatic insufficiency
Age at
diagnosis
(years) Details
2 36 Female Mutation
(c.982_986delCCTCT)
Diagnosed at age 20
years, on insulin
90 39 FE-1 measured by renal team after
several months of abdominal pain
and diarrhoea; resolution of symp-
toms and weight gain after treat-
ment commenced
3 61 Female Deletion
(c.1-?_1674þ? del)
Haemoglobin A1c of 56
mmol/mol identified
at age 59 years but
no treatment
commenced
31 63 Known pancreatic atrophy and calcifi-
cation from previous imaging for
abdominal pain under surgical
team. FE-1 measured by gastroen-
terology after referral with several
months of abdominal pain, loose
stools and weight loss; improve-
ment in symptoms and 6-kg weight
gain after pancreatic enzyme
replacement therapy commenced
18 43 Female Deletion
(c.1-?_1674þ? del)
Diagnosed at age
32 years, on insulin
107 43 Referred to gastroenterology with
abdominal pain, diarrhoea (with
occasional blood mixed in) and
weight loss; colonoscopy performed
and found to be normal. FE-1 meas-
ured by research team; commenced
on pancreatic enzyme replacement
therapy with symptomatic
improvement
del, deletion; FE-1, faecal elastase-1.
Fig. 2. Bar charts showing the percentage of individuals with HNF1B-associated disease according to diabetes status with faecal elastase-1 (FE-1) measurements (A)
either below or above the 2.5 percentile of a healthy control cohort and (B) <100 mg/g stool (suggestive of severe pancreatic exocrine insufficiency), 100–200 mg/g stool
(moderate to mild insufficiency), 200–500 mg/g stool and >500 mg/g stool.
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elastase deficiency in association with an HNF1B mutation have
usually been from smaller series of patients with diabetes or
prediabetes [8, 9, 18, 20]. Tjora et al. [18] included one patient
with an HNF1B mutation and normal glucose tolerance in their
study of exocrine pancreatic function using direct testing; this
individual was 38 years old with normal pancreas anatomy on
imaging and a faecal elastase-1 measurement of 312 mg/g stool.
An earlier study from the same group recruited an affected 6-
year-old girl with no pancreatic body and tail identified on
imaging and a faecal elastase-1 concentration of 131 mg/g stool;
she had developed impaired glucose tolerance when studied
again at the age of 8 years [9, 18]. We included 15 HNF1B
patients without diabetes in this study; 7/15 (47%) had a low fae-
cal elastase-1 measurement but only 1/15 (7%) had a measure-
ment of <200 mg/g stool. We would hypothesize that pancreatic
insufficiency and diabetes in HNF1B-associated disease are
associated, as they are secondary to reduced exocrine and endo-
crine cells as a result of pancreatic hypoplasia. However, cau-
tion must be applied when interpreting the results between the
HNF1B cohorts with and without diabetes, as any differences
may reflect the discrepancy in age between the two groups. It
would be very interesting in future work to follow a cohort of
paediatric patients with HNF1Bmutations over time using serial
indirect pancreatic function testing and imaging to see if these
non-invasive tests can be used to predict who will develop dia-
betes and exocrine insufficiency and at what age.
Several limitations were associated with this work. The
cohort of healthy controls used to define the lower limit of the
normal range for faecal elastase-1 were older; the median age
was 61.7 years (IQR 52.8–66.3) compared to 24.5 years (IQR 14–44)
in the individuals with HNF1B-associated renal disease.
However, faecal elastase concentrations decline with age, so
defining a cut-off for faecal elastase-1 using the 2.5 percentile of
a younger control cohort may have yielded an even greater
value than the 410 mg/g stool used in this study [25]. The median
faecal elastase-1 measurement of 1580 mg/g stool (IQR 1000–
2000) in our local control cohort is higher than values reported
for healthy controls in other studies [25–27]. This may reflect
assay differences between laboratories but, as we have defined
low faecal elastase-1 as measurements that fall below the 2.5
percentile of a local healthy control group, this make our results
generalizable. Furthermore, we found that our local cut-off of
410 mg/g stool correlated with the presence or absence of pan-
creatic hypoplasia on radiological imaging. Finally, our small
sample size of 29 individuals with HNF1B-associated disease
means we may have been underpowered to make definitive
comments on the comparison of patients with and without
diabetes.
There is no consensus as to when HNF1B genetic testing
should be performed. Two tools have been developed in recent
years to help select individuals who would benefit from screen-
ing: the HNF1B score designed by Faguer et al. [28] and adapted
criteria for HNF1B analysis proposed by Raaijmakers et al. [29].
However, faecal elastase was not systematically assessed in
either of these studies. It is cheap and easy to measure, requir-
ing only a single spot stool sample. Given that low faecal
elastase-1 concentrations were seen in 18/29 (62%) patients
with HNF1B-associated renal disease in this study, it would be
interesting to test the role of faecal elastase-1 as a biomarker for
HNF1B-associated disease in a large cohort of individuals with
congenital anomalies of the kidneys and urinary tract. In the
interim, we suggest that the finding of a low faecal elastase
measurement in individuals with developmental kidney dis-
ease of uncertain cause should prompt referral for HNF1B
genetic testing.
Conclusion
In summary, faecal elastase-1 deficiency is an important feature
of HNF1B-associated renal disease even when diabetes is not
present. Faecal elastase-1 should be measured in all individuals
with an HNF1B mutation complaining of abdominal pain, loose
stools or unintentional weight loss. The role of faecal elastase-1
as a biomarker for HNF1B-associated disease requires further
investigation.
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Table 2. Characteristics of individuals with HNF1B-associated disease according to diabetes status
Feature HNF1B-associated disease, no DM (n ¼ 15) HNF1B-associated disease with DM (n ¼ 14) P-value
Age (years), median (IQR) 14 (9–19) 43.5 (34–55) 0.0005
Sex, n (%) Male 9 (60), Female 6 (40) Male 4 (29), Female 10 (71) 0.1
Genetic abnormality, n (%) Mut 9 (60), del 6 (40) Mut 7 (50), del 7 (50) 0.7
BMI (kg/m2), median (IQR) 20 (18–27) 23 (20–25) 0.1
Creatinine (mmol/L), median (IQR) 79 (55–115) 116 (90–144) 0.03
HbA1c (mmol/mol), median (IQR) 39 (37–42) 60 (55–74) 0.0005
UCP:Cr ratio (nmol/mmol), median (IQR) 2.1 (1.4–5.6) 1.1 (0.6–1.5) 0.04
del, deletion; DM, diabetes mellitus; mut, mutation.
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